CytomX Therapeutics (CTMX) Current Assets (2014 - 2026)

CytomX Therapeutics has reported Current Assets for 13 years, with the latest figure at $353.1 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 307.6% year-over-year to $353.1 million; the trailing twelve-month figure through Mar 2026 stood at $353.1 million (up 307.6% YoY), and the FY2025 full-year result was $143.9 million, up 34.12% from the prior year.
• Current Assets for Q1 2026 stood at $353.1 million, up from $143.9 million in the prior quarter.
• The five-year high for Current Assets was $353.1 million in Q1 2026, with the low at $86.6 million in Q1 2025.
• Historically, Current Assets has averaged $186.0 million across 5 years, with a median of $182.9 million in 2023.
• Annual changes were most pronounced in 2025 — Current Assets slumped 48.2% — and 2026, when it surged 307.6%.
• CytomX Therapeutics' Current Assets stood at $237.1 million in 2022, then slipped by 22.85% to $182.9 million in 2023, then sank by 41.34% to $107.3 million in 2024, then jumped by 34.12% to $143.9 million in 2025, then surged by 145.34% to $353.1 million in 2026.
• The last three Current Assets figures came in at $353.1 million (Q1 2026), $143.9 million (Q4 2025), and $149.2 million (Q3 2025), per Business Quant data.